Wuhan Ammunition Life-tech Co., Ltd. (referred to as "Ammunition") has recently submitted its listing application to the Hong Kong Stock Exchange, with joint sponsors CCB International and BOCOM International.

Founded in 2015, Ammunition specializes in emerging cancer early-screening technologies. The company claims its flagship product, Aiguangle, can detect urothelial carcinoma non-invasively using just 1 milliliter of urine. However, despite its cutting-edge technology, the company remains unprofitable, with questionable R&D expenditures and significant related-party transactions.

**Focus on Early Cancer Screening** Public awareness of early cancer prevention and treatment has grown in recent years. Traditional diagnostic methods, such as endoscopy and biopsy, often deter patients due to discomfort and psychological resistance. Ammunition highlights in its prospectus that "low patient compliance persists for liver and urothelial cancers due to the invasive nature of traditional tests like biopsies and cystoscopies."

Consequently, cancer early-screening companies, including Ammunition, emphasize painless convenience and rapid results as core competitive advantages.

Ammunition has developed a pipeline of over 10 early-screening products, five of which have obtained Class III medical device approval in China. These include Aichangkang and Aichangjian for colorectal cancer, Aisining for esophageal cancer, Aixingan for liver cancer, and Aigongshu for cervical cancer. Several other candidates remain in development.

Notably, all five approved products are classified as "in vitro diagnostic reagents" rather than registered early-screening tools. Currently, China has very few approved cancer early-screening products, with Nuohui Health's Changweiqing securing the first such registration in November 2020.

In August this year, China's National Medical Products Administration issued stricter guidelines for clinical evaluations of cancer screening diagnostic reagents, requiring multi-center trials across at least three institutions.

**Significant Related-Party Transactions** Ammunition's financial performance reveals heavy reliance on related-party transactions.

From 2023 to the first half of 2025, the company reported revenues of RMB 6.23 million, RMB 7.24 million, and RMB 6.51 million, respectively. While H1 2025 revenue doubled year-on-year, total revenue remains below RMB 10 million. Net losses during the same period were RMB 67.92 million, RMB 38.63 million, and RMB 13.91 million, showing narrowing losses but no clear path to profitability.

More concerning is Ammunition's client concentration. From 2023 to H1 2025, its top five clients contributed 69.3%, 73.2%, and 76.7% of total revenue. Wuhan Ainuo Medical Laboratory, wholly owned by Ammunition’s executive director and controlling shareholder Zhang Lianglu, accounted for 44.5% and 52.1% of revenue in 2023 and 2024, respectively.

Another major client, Guangdong Hybribio, is linked to Hybribio Biopharm (300639.SZ), Ammunition’s second-largest shareholder with an 11.69% stake. The prospectus describes Hybribio as a "seasoned investor" and partner in developing Aigongshu.

**Questionable R&D Spending** Ammunition’s R&D expenditures have declined sharply, from RMB 22.74 million in 2023 to RMB 4.52 million in H1 2025. While R&D costs once accounted for 364.8% of revenue, the trend raises concerns compared to industry peers.

Curiously, the company pays its R&D and sales teams nearly identical salaries. As of H1 2025, Ammunition employed 82 staff, including 28 R&D and 31 sales personnel. In H1 2024, R&D salaries totaled RMB 5.21 million versus sales’ RMB 5.37 million; in H1 2025, these figures were RMB 2.67 million and RMB 3.95 million, respectively.

The prospectus touts an "experienced R&D team" that shortened development cycles to 4.5 years, citing Aixingan’s 4-year-4-month timeline.

The industry faces heightened scrutiny after Nuohui Health (06606.HK), once China’s "first cancer early-screening stock," delisted in 2025 following a financial fraud scandal involving falsified test data.